跳至主要内容
临床试验/NCT05930912
NCT05930912进行中(未招募)不适用

Psychiatric Orders in Psychoanalytic Treatment of ASD

Yang I. Pachankis, PhD1 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2023年6月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
1
试验地点
1
主要终点
Generalized Anxiety Disorder (GAD-7)

研究概览

简要总结

Autism Spectrum Disorder (ASD) is often accompanied by a variety of other symptoms, such as bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), Social Anxiety Disorder (SAD), Avoidant Personality Disorder (AvPD), Obsessive Compulsive Disorder (OCD), etc. The behavioral and social complications often marginalize the population, impact on life satisfaction, undermined societal values that impact on economic and financial fairness, and so forth. Furthermore, persons with ASD are neurodiverse from standardized pharmacological and clinical cares, and are interpreted disadvantaged in the context of neurotypical treatments.

The research protocol aims to differentiate the neuropharmacological implications of ASD from its behavioral and social implications. Such a differentiation is beneficial to the quality of care for neurodiverse population, both in terms of precision treatment in medical settings, and in terms of psychotherapeutic treatment efficacy in the interpretation of behavioral and social traits.

The study protocol continues from the adverse event of the participant in NCT05711810 trial, after the positive immunological results in the NCT05839236 trial. The intervention medicine continues from Sertraline adjusted on the choice of Selective Serotonin Reuptake Inhibitor (SSRI) in the previous two trials for complex post-traumatic stress disorder (CPTSD) of the participant, and its combined used with Duloxetine in the choice of Selective Norephedrine Reuptake Inhibitor (SNRI) for norephedrine regulations.

The hypothesized target is on the discrete psychiatric intervention centered approach to ASD treatment care. In the PRC where the study is being carried out, amphetamine class medicines are strictly prohibited and defined as illegal substances, regardless of their only proven effect for ASD patient care. Contributed by the sociostructural elements and necessities, black market amphetamine and ketamine have not only emerged in the regime for decades, but also have become a lucrative business. Their recreational uses are also sometimes accompanied by real necessities and needs; black markets cater to the needs but guidance on the usages is based on word-of-mouth stories without professional medical assistances. There is one case the Principal Investigator (PI) collected, that one person, possibly under depression contributed by PTSD, took relatively high dosage of amphetamine and went into a state of psychosis with overwhelming persecution mania. The study protocol, Psychiatric Orders in Psychoanalytic Treatment of ASD, is therefore designed for an evidence-based approach in treating complex psychiatric disorders with psychoanalytic guidance.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Persons with ASD.

排除标准

  • Severe ASD cases with central nerve system complications.

研究组 & 干预措施

Participant Case

The participant started taking SNRI duloxetine 20 mg/night in Jan. 2023, and changed to SSRI sertraline 50 mg/d in Mar. 2023. The apparent positive psychedelic effects did not take effect until increased dosage to sertraline 100mg/d after around one week in Jun. 2023. Duloxetine is planned to be added to the mix thereon.

干预措施: Psychoanalysis (Diagnostic Test)

Participant Case

The participant started taking SNRI duloxetine 20 mg/night in Jan. 2023, and changed to SSRI sertraline 50 mg/d in Mar. 2023. The apparent positive psychedelic effects did not take effect until increased dosage to sertraline 100mg/d after around one week in Jun. 2023. Duloxetine is planned to be added to the mix thereon.

干预措施: sertraline 50mg (Drug)

Participant Case

The participant started taking SNRI duloxetine 20 mg/night in Jan. 2023, and changed to SSRI sertraline 50 mg/d in Mar. 2023. The apparent positive psychedelic effects did not take effect until increased dosage to sertraline 100mg/d after around one week in Jun. 2023. Duloxetine is planned to be added to the mix thereon.

干预措施: Duloxetine 20 MG (Drug)

Participant Case

The participant started taking SNRI duloxetine 20 mg/night in Jan. 2023, and changed to SSRI sertraline 50 mg/d in Mar. 2023. The apparent positive psychedelic effects did not take effect until increased dosage to sertraline 100mg/d after around one week in Jun. 2023. Duloxetine is planned to be added to the mix thereon.

干预措施: Cognitive Behavioral Therapy (Behavioral)

结局指标

主要结局

Generalized Anxiety Disorder (GAD-7)

时间窗: 90 days

Severity Measure for Agoraphobia-Adult

时间窗: 90 days

BPD Check List

时间窗: 90 days

Rosenberg Self-Esteem Scale (RSE)

时间窗: 90 days

The Defeat Scale (D Scale)

时间窗: 90 days

Behavioral Satisfaction Questionnaire (Y axis)

时间窗: 90 days

The Y axis score total range -200 to +195, from inhibition to excitation of the hypothalamic-pituitary-adrenal (HPA) axis in daily lives.

Dissociative Experiences Scale - II (DES-II)

时间窗: 90 days

Personality Belief Questionnaire (PBQ)

时间窗: 90 days

Hamilton Anxiety Rating Scale (HAM-A)

时间窗: 90 days

Yale-Brown Obsessive Compulsive Scale (Y-BOCS)

时间窗: 90 days

Young Schema Questionnaire (YSQ)

时间窗: 90 days

Behavioral Satisfaction Questionnaire (X axis)

时间窗: 90 days

The X axis score total range -150 to +140, from self-centrism (passive-aggressiveness) to proactive social behaviors.

次要结局

  • Heart Rate(90 days)
  • Systolic Blood Pressure(90 days)
  • Diastolic Blood Pressure(90 days)

研究者

发起方
Yang I. Pachankis, PhD
申办方类型
Indiv
责任方
Sponsor Investigator
主要研究者

Yang I. Pachankis, PhD

PI

Pachankis, Yang I., M.D.

研究点 (1)

Loading locations...

相似试验